Pediatric Psychopharmacology in Primary Care Part 2: Mood & Anxiety

Alison Schonwald MD

Dept. of Pediatrics, Cambridge Health Alliance Associate Professor, Harvard Medical School Touchstone Neurodevelopmental Center



Disclosure

I have no relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in this CME activity.

I <u>do</u> intend to discuss unapproved/investigative use of commercial products in my presentation. Learning Objectives Evaluate and update your use of valid screening and monitoring tools for pediatric anxiety and mood disorders

Choose approved and/or effective medications when treating pediatric anxiety and mood disorders



CASE 1: Cam

8-year-old 2nd grader 10 mg Focalin XR & 3 mg melatonin

Returns for routine care 12-year-old visit


Cam at 12

Irritable, tearful, clingy, does not want to do things he used to enjoy

"I wish I weren't here"

No trauma, has 504 Plan and sees school counselor

Pediatric Symptom Checklist, PHQ-9: elevations



Behavioral and Emotional Screener: School-age & Adolescents Strengths and Difficulties Questionnaire

Pediatric Symptom Checklist - 17

Pediatric Symptom Checklist - 35

Screens for Anxiety and Depression

(Practice Change?)

Depression


- PHQ-9 and PHQ-2 (12 yrs +)
 - <u>https://www.apa.org/depression-guideline/patient-health-</u> <u>questionnaire.pdf</u>
 - <u>https://www.med-</u> iq.com/files/noncme/material/pdfs/Llo42%20IG%20tools.pdf
- Moods and Feelings Questionnaire (6-19 yrs)
 - <u>https://devepi.duhs.duke.edu/measures/the-mood-and-feelings-questionnaire-mfq/</u>

Anxiety

- SCARED (8-18yrs)
 - <u>https://www.pediatricbipolar.pitt.edu/resources/instruments</u>
- Spence (3 yrs +)
 - <u>https://www.scaswebsite.com/</u>

What would you do?

Refer	1. Refer to outside therapy
Stop	2. Stop Focalin XR
Start	3. Start SSRI




ADHD and Co-Morbid Diagnoses

Oppositional Defiant Disorder	30-50%
Depression	29-45%
Bipolar Disorder	20%
Anxiety	~25%
Learning Disability	20-25%
Tic Disorder	20%

Depression Presentation in Children

- Less persistent and consistent than in adults
- More bored, irritable or angry than sad
- Early signs: less social initiative, family activity







Now would you start an SSRI?

Which SSRI?


SSRI Indications: Depression

Generic	Brand	Age	Approval	Notes
Fluoxetine	Prozac	≥8 y	Depression	±Long ½ life
Escitalopram	Lexapro	≥12 y	Depression	+Few interactions
Citalopram	Celexa		1 + study in 7- 17 yr olds	Max dose= 40 mg b/c QTc
Sertraline	Zoloft		2 + studies in 6- 17 yr olds	
Paroxetine	Paxil			

Generic	Brand	Dose in mg	Notes
Buproprion	Wellbutrin SR	37.5-400	-Seizure risk +ADHD treatment
Venlafaxaine	Effexor XR	37.5-225	-HTN risk +Effective for teens +Anxiety treatment
Desvenlafaxine	Pristiq	50-400	
Mirtazapine	Remeron	15-45	±Weight gain ±Sedation -Negative RCT findings
Duloxetine	Cymbalta	20-60	SNRI

Other medications (OFF-LABEL): Depression


Treatment for Adolescents with Depression Study (TADS)



March J, et al: (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry 2006; 45:1393–1403

Treatment for Adolescents with Depression Study (TADS)

n=439, 12-17 yo



http://www.nimh.nih.gov/funding/clinical-trials-forresearchers/practical/tads/questions-and-answersabout-the-nimh-treatment-for-adolescents-withdepression-study-tads.shtml Negative Studies for Major Depression in Children

- Citalopram
- Escitalopram
- Paroxetine
- Mirtazapine
- Nefazadone
- Venlafaxine

Similar response rates, higher placebo rates


Soutullo C, Figueroa-Quintana A. When do you prescribe antidepressants to depressed children? Curr Psychiatry Rep. 2013 Jul;15(7):366.

Generic	Brand	Age	Approval	Notes
Fluoxetine	Prozac	≥7 y	OCD	± Long ½ life
Sertraline	Zoloft	≥6 y	OCD	
Fluvoxamine	Luvox	≥8 yr	OCD	
Duloxetine	Cymbalta	7-17 yr	GAD	Weight loss, $ riangle$ HR & BP
Venlafaxine	Effexor			+ RCT Gen & Social Anxiety - HTN
Buspirone	Buspar			No data in youth
Buproprion	Wellbutrin			No data in youth

Medications: Anxiety

Childhood Anxiety Multimodal Study (CAMS)

- RCT non-OCD anxiety do
- 12-weeks, n= 488
- SAD, GAD, Social phobia
- ➢All 3 active treatment arms: superior responses vs. placebo



Walkup JT, Piacentini J, Birmaher B, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008;359(26):2753–66.

EVIDENCE for SSRI/SNRI to treat Pedi/Adol. Anxiety

Kodish I, Rockhill C, Ryan S, Varley C. Pharmacotherapy for Anxiety Disorders in Children and Adolescents. Pediatr Clin N Am 58 (2011) 55–72.

Leonte, Puliafico, Na, Rynn. Up To Date: Pharmacotherapy for Anxiety Disorders in Children and Adolescents. Jan 2019.

Medication	Trial type	Finding
Fluoxetine, Fluvoxamine, Paroxetine, Sertraline	RCT	Improved in OCD
Fluoxetine, Fluvoxamine, Sertraline, Venlafaxine, Duloxetine	RCT	Improved Generalized Anxiety Disorder
Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Venlafaxine	RCT	Improved Social Phobia or Social Anxiety
Fluoxetine, Sertraline	RCT	Improved Selective Mutism
Citalopram	Open-label	Improved OCD
SSRI and SNRI	Meta-analysis	Double response rate of placebo

What I might do

Has either parent taken an SSRI?

Sertraline 6.25 mg PO QAM

Increase to 12.5 mg in 3 weeks if no problems, no improvement

Return 6 weeks

Ask school counselor to do weekly check-ins

What information about SSRIs do you give parents when prescribing?

SSRI Side Effects

CNS (agitation, disinhibition, restless, insomnia, sedation, headache, tremor, apathy)


Appetite, weight gain or loss, nausea, diarrhea

Sexual effects (dose related anorgasmia)

Side Effect: Activation

10.7% children (2.1% adolescents)

Irritability, mild disinhibition, increased restlessness and insomnia



Strawn JR, Dobson ET, Giles LL. Primary Pediatric Care Psychopharmacology: Focus on Medications for ADHD, Depression, and Anxiety. *Curr Probl Pediatr Adolesc Health Care*. 2016;47(1):3-14.

Black Box Warning 10/04: All antidepressants for children and Possible new-onset adolescents suicidalideation may be related to

behavioral

activation

akathesia, mania, or

acute delirium

Twofold increase from 2% to 4% reporting suicidal ideation or behaviors

No suicides occurred in these trials

Review of 27 studies

Patients w/ depression, anxiety, OCD

Antidepressants vs. placebo

Rate suicidal ideation/attempts:

3% vs. 2%

Risk difference not statistically significant

No completed suicide

Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment. A meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683–96


Depression Monitoring

FDA Recommendation

- Wkly visits x 1 mo, every other wk x 1 mo, at 12 wks
- Reality
 - ~40% have <3 visits in the first three months
 - Fewer than 5% receive this level of supervision

MorratoEH, LibbyAM, OrtonHD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008;165(1):42–50. When SSRIs don't work:

Cross Taper



Dose

25

5

12.5

6.25

10

10

SSRI

Brand name (generic name)	Age and approved indications	Off-label clinical indications	Metabolism	Preparation	Start dose per day	Target dose per day
Celexa [®] (citalopram)	No pediatric approval	Depression, anxiety, OCD	Weak IID6, IIIA4, IIC19	10, 20, 40 mg 10 mg/5 mL	5–10 mg	10-40 mg
Lexapro [®] (escitalopram)	<u>></u> 12 y0: depression	Anxiety	Weak IID6, IIIA4, IIC19	5, 10, 20 mg 5 mg/5 mL	1.25–5 mg	2.5–20 mg
Luvox [®] (fluvoxamine)	≥8 yr: OCD	Depression, anxiety	IA2, IIIA3–4, IIC19	25, 50, 100 mg; 100, 150 mg ER	12.5–25 mg	25–200 mg
Paxil[®] (paroxetine)	No ped. approval; not recommended for depression < 18 yr	Anxiety, OCD	IID6, IIIA4	10, 20, 30, 40 mg; 12.5, 25, 37.5 mg CR 10 mg/5 mL	5–10 mg	10–60 mg
Prozac [®] (fluoxetine)	≥ 8 yr: depression ≥7 yr: OCD	Anxiety	IID6, IIIA3– 4, IIC19	10, 20, 40 mg 20 mg/5 mL	2.5–10 mg	5-20 mg MDD 20-60 mg OCD
Zoloft [®] (sertraline)	≥6 yr: OCD	Depression, anxiety	Weak IID6, IIC19	25, 50, 100 mg 20 mg/mL	12.5–50 mg	25–200 mg


Buspirone (Buspar) in HFA

- (2018) Retrospective Chart Review of Buspirone for the Treatment of Anxiety in Psychiatrically Referred Youth with High-Functioning Autism Spectrum Disorder
- 31 patients
- Significant improvement in anxiety symptoms (CGI-I ≤ 2) was observed in 58% and mild improvement (CGI-I = 3) in 29% of the HF-ASD patients

Desvenlafaxine (Pristiq)

- Approval-adults only
- (2017) Low and high exposure desvenlafaxine groups did not demonstrate efficacy for the treatment of MDD in children and adolescents in this double-blind, placebo-controlled trial.
- Desvenlafaxine (20-50 mg/day) was generally safe and well tolerated with no new safety signals identified in pediatric patients with MDD in this study.

Take Home





Start low, increase slowly

Over a week? Every 3 weeks?



Clear benefit at 2-4 weeks



Most side effects resolve in first few weeks



Promoting Optimal Development: Screening for Behavioral and Emotional Problems

Carol Weitzman, MD, FAAP, Lynn Wegner, MD, FAAP, the SECTION ON DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, COMMITTEE ON PSYCHOSOCIAL ASPECTS OF CHILD AND FAMILY HEALTH, COUNCIL ON EARLY CHILDHOOD, AND SOCIETY FOR DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS

School-age and adolescent children	Strengths and Difficulties Questionnaire	3—17 у	25 items	Parent/teacher 4–10-y-old; parent/ teacher 11–17-y-old; youth self report 11–17-y-old; parent/teacher/ self follow-up forms available	Variable across cultural groups; sensitivity: 63%–94%, specificity: 88%–96%; available in >70 languages	http://www.sdqinfo.org
	Pediatric Symptom Checklist—17	4—16 у	17 items	Parent completed; youth self-report >10 y; pictorial version available	Variable psychometrics for detection of psychiatric problems; available in multiple languages	http://www.massgeneral.org/psychiatry/ services/psc_home.aspx
	Pediatric Symptom Checklist—35	4—16 у	35 items	Parent completed; youth self-report >10 y; pictorial version available	Sensitivity: 80%–95%, specificity: 68%–100%; available in multiple languages	http://www.massgeneral.org/psychiatry/ services/psc_home.aspx

https://publications.aap.org/pediatrics/article/135/2/384/33387/ Promoting-Optimal-Development-Screeningfor?autologincheck=redirected Workbooks and Books for Children


- <u>Anxiety Relief Workbook for Kids: 40</u> <u>Mindfulness, CBT and ACT Activities to</u> <u>Find Peace from Anxiety and Worry (Agnes</u> Selinger, PhD, ages 6-9)
- 2. <u>Starving the Anxiety Gremlin for Children</u> aged 5-9 (Kate Collins-Donnelly)
- 3. <u>Starving the Anger Gremlin: A Cognitive</u> <u>Behavioral Therapy Workbook on Anger</u> <u>Management for Young People</u> (Kate Collins-Donnelly 10-16 yrs)

Free Workbooks for Teens

- https://dochub.com/mistybonta/B5LgrG vRo7x3EZ2w9MYq6j/the-angerworkbook-for-teens-pdf?dt=aF-MCWO2EVkX62GPzskw&pg=19 (The Anger Workbook for Teens, 2nd Edition, Raychelle Cassada Lohmann, PhD LPC)
- 2. <u>http://www.tri-co-cac.org/files/social-emotional-learning-workbook-for-teens.pdf</u> (Social Emotional Work Book for teens, free one-user license)

Mindfulness Apps

Calm Headspace (for kids) Smiling Mind Three Good Things: A Happiness Journal Insight Timer Dreamy Kid Mindful Powers Stop, Breathe and Think Kids



Very useful references as resources

- Southammakosane C, Schmitz K. Pediatric Psychopharmacology for Treatment of ADHD, Depression, and Anxiety. Pediatrics Aug 2015, 136 (2) 351-359.
- Strawn, Dobson, Giles. Primary Pediatric Care Psychopharmacology: Focus on medications for ADHD, depression and anxiety. Curr Probl Pediatr Adolesc Health Care. 2017 January ; 47(1): 3–14.
- 3. Sharma, A. (2018). Update on common psychiatric medications for children. *Pediatric Annals, 47*(8), 311-316.
- 4. Fung, et al. Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Metaanalysis. Pediatrics Feb 2016, 137 (Supplement 2) S124-S135.

Additional References

- 1. Chhangani et al. Pharmacology of Sleep Disorders in Children and Adolescents. Pediatr Clin N Am 58 (2011) 273–291.
- 2. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Diabetes Care February 2004 vol. 27 no. 2 596-601.
- 3. Margari et al. Tolerability and safety profile if risperidone in a sample of children and adolescents. International Clin Psychopharm 28 (2013) 177-183.
- 4. Mohatt et al. Treatment of Separation, Generalized, and Social Anxiety Disorders in Youths. Am J Psychiatry 2014;171:741-748.
- 5. Ceranoglu TA, Wozniak J, Fried R, Galdo M, Hoskova B, DeLeon Fong M, Biederman J, Joshi G. A Retrospective Chart Review of Buspirone for the Treatment of Anxiety in Psychiatrically Referred Youth with High-Functioning Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2019 Feb;29(1):28-33.